Financials in USD. Standardized financial statements.
A compact view of how Repare Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $53.48M | $51.13M | $131.83M | $7.60M | $135,000 | $0 | $0 | $0 |
| Revenue Growth? | +4.6% | -61.2% | +1634.6% | +5529.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $13.38M | $13.24M | $116.72M | $87.85M | $38.77M | $968,000 | $407,000 | $102,000 |
| Gross Profit? | $40.10M | $37.89M | $15.11M | -$80.25M | -$38.64M | -$968,000 | -$407,000 | -$102,000 |
| Gross Margin? | +75.0% | +74.1% | +11.5% | -1056.0% | -28622.2% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $133.62M | $154.12M | $34.90M | $28.41M | $15.66M | $24.84M | $12.82M | $6.17M |
| Operating Income? | -$93.52M | -$116.22M | -$19.80M | -$108.66M | -$54.30M | -$25.81M | -$12.82M | -$6.17M |
| EBITDA? | -$90.22M | -$114.27M | -$17.82M | -$107.19M | -$53.41M | -$25.49M | -$13.51M | -$7.53M |
| Income Before Tax | -$83.25M | -$103.18M | -$13.90M | -$108.59M | -$54.74M | -$26.45M | -$14.25M | -$7.80M |
| Income Tax Expense | $1.44M | -$9.38M | $15.15M | -$1.68M | -$1.32M | $761,000 | $35,000 | $0 |
| Net Income? | -$84.69M | -$93.80M | -$29.05M | -$106.91M | -$53.42M | -$27.22M | -$14.28M | -$7.80M |
| EPS? | $-2.00 | $-2.23 | $-0.69 | $-2.83 | $-1.45 | $-0.74 | $-0.90 | $-0.49 |
| Diluted EPS? | $-2.00 | $-2.23 | $-0.69 | $-2.83 | $-1.45 | $-0.74 | $-0.90 | $-0.49 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality